Nachrichten zur Sage Therapeutics Aktie

Sage Therapeutics Q4 Earnings Miss Mark, Revenues Plunge Y/Y

SAGEs earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression…

Sage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call Transcript

…

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do…

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

Sage Therapeutics (SAGE) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Key deals this week: Molson Coors Beverage, Emerson Electric, Sage Therapeutics and more

…

SAGE Rejects Biogens Offer to Buy Remaining Stake, Stock Up

Sage Therapeutics turns down Biogens offer to buy the remaining stake in the company and is evaluating strategic alternatives to…

Sage Therapeutics: Biogens Unsolicited Bid Is Best Step Forward For Shareholders

…

Sage Therapeutics Jumps on Biogen’s $469 Million Offer

Shares of Sage Therapeutics Inc. surged after Biogen Inc. offered to acquire the neuroscience-focused drugmaker for about $469 million.…

Sage Therapeutics shares surge on unsolicited takeover bid from Biogen

Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB,...…

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.…

Biogen Aktie: Positive Resonanz auf Neues!

Der US-Biotechnologiekonzern Biogen plant einen strategischen Schritt zur Erweiterung seines Portfolios. Das Unternehmen hat ein Angebot zur Übernahme der verbleibenden…

Biogen proposes to buy remaining stake in Sage in $442 million deal

Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a…

SAGEs Dalzanemdor Fails to Meet Goal in Huntingtons Disease Study

Sage Therapeutics pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntingtons disease fails to meet…

Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript

…

SAGEs Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Sage Therapeutics third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.…

Sage Therapeutics, Inc. 2024 Q3 - Results - Earnings Call Presentation

…

SAGE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Sage Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion

LOS ANGELES, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Methode Electronics, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

SAGE DEADLINE NOTICE: Rosen, A HIGHLY RECOGNIZED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

SAGE DEADLINE: RLF, A TOP-RANKED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE

NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- WHY:Rosen Law Firm, a global investor rights law firm,…

ROSEN, A TOP-RANKED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments.…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

SAGEs Dalzanemdor Fails to Meet Goal in Alzheimers Disease Study

The phase II LIGHTWAVE study evaluating Sage Therapeutics dalzanemdor for treating cognitive issues due to Alzheimers disease fails to meet…

Sage Therapeutics stock drops after disappointing Alzheimers trial results By Investing.com

Sage Therapeutics stock drops after disappointing Alzheimers trial results…

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

…

ROSEN, A RANKED AND LEADING FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm

NEW YORK, Oct. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

SAGE REMINDER – Robbins LLP Urges SAGE Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff Deadline

Robbins LLP is Investigating Allegations that Sage Therapeutics, Inc. (SAGE) Misled Investors Regarding the Efficacy of its New Drugs…

ROSEN, LEADING INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for Investors – Contact The Gross Law Firm

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)

LOS ANGELES, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Methode Electronics, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sage, Outset Medical, Allarity, and Super Micro and Encourages Investors to Contact the Firm

NEW YORK, Sept. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Sept. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To…

SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline

SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

SAN DIEGO, Sept. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…